tirofiban has been researched along with No-Reflow Phenomenon in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, H; Hu, X; Lin, Y; Wang, W; Ye, J; Yu, B; Zhou, L; Zhou, Y | 1 |
| Chen, MH; Qin, T; Xie, L | 1 |
| Arif Yalcin, A; Biyik, I; Celik, O; Erturk, M; Faruk Akturk, I; Murat Caglar, I; Oner, E; Sarikamis, C; Turhan Caglar, N; Uzun, F | 1 |
| Akpek, M; Arinc, H; Baktir, AO; Ergin, A; Kaya, MG; Oguzhan, A; Saglam, H; Sahin, O; Sarli, B; Urkmez, S | 1 |
| Aparci, M; Balta, S; Celik, T; Demir, M; Demirkol, S; Iyisoy, A; Kaya, MG; Kilic, S; Ozturk, C; Unlu, M; Yildirim, OA | 1 |
| Badran, AV; Barbosa, R; Figueiredo, GL; Haddad, JL; Lago, IM; Lima, MO; Marin, JA; Novaes, GC; Pavão, RB; Schmidt, A | 1 |
| Cunha, MS; da Silva, JC; Ferreira, MC; Machado, FA; Nakamoto, HA | 1 |
| Anselmi, M; Biondi-Zoccai, G; Boccuzzi, G; Bolognese, L; Campo, G; de Cesare, N; Díaz Fernández, JF; Ferrari, R; Malagutti, P; Moreno, R; Parrinello, G; Penzo, C; Ribichini, F; Rodriguez, AE; Russo, F; Valgimigli, M | 1 |
2 review(s) available for tirofiban and No-Reflow Phenomenon
| Article | Year |
|---|---|
Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon.
Topics: Coronary Vessels; Humans; Injections, Intra-Arterial; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and S
Topics: Abciximab; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Agents; Coronary Angiography; Coronary Circulation; Drug-Eluting Stents; Evidence-Based Medicine; Female; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sirolimus; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
3 trial(s) available for tirofiban and No-Reflow Phenomenon
| Article | Year |
|---|---|
Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction.
Topics: Adenosine; Aged; Female; Fibrinolytic Agents; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Prognosis; Prospective Studies; Survival Rate; Tirofiban; Tyrosine; Vasodilator Agents; Verapamil | 2014 |
Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Aged; Coronary Circulation; Coronary Thrombosis; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Stents; Time Factors; Tirofiban; Treatment Outcome; Turkey; Tyrosine | 2015 |
In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study.
Topics: Aged; Brazil; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Pilot Projects; Placebos; Platelet Aggregation Inhibitors; Postoperative Complications; Predictive Value of Tests; Stents; Time Factors; Tirofiban; Tyrosine | 2016 |
3 other study(ies) available for tirofiban and No-Reflow Phenomenon
| Article | Year |
|---|---|
Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.
Topics: Aged; China; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome | 2021 |
Predictors of No-Reflow Phenomenon in Young Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adult; Age Factors; Chi-Square Distribution; Coronary Circulation; Female; Humans; Logistic Models; Lymphocyte Count; Male; Mean Platelet Volume; Middle Aged; No-Reflow Phenomenon; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Retrospective Studies; Risk Factors; Sex Factors; ST Elevation Myocardial Infarction; Time Factors; Time-to-Treatment; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Effect of IIb-IIIa glycoprotein inhibitors in a partial limb amputation model submitted to warm ischemia in rats.
Topics: Abciximab; Amputation, Surgical; Animals; Antibodies, Monoclonal; Hindlimb; Immunoglobulin Fab Fragments; Limb Salvage; Male; Microcirculation; Models, Animal; No-Reflow Phenomenon; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Rats, Wistar; Tirofiban; Tyrosine; Warm Ischemia | 2009 |